In the RESHAPE-HF2 trial, 505 patients with systolic HF (left ventricular ejection fraction 20-50% and New York Heart Association [NYHA] class II-IV HF symptoms) and moderate to severe functional MR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results